PPAR delta is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
The Viceroyalty of New Granada was established in 1717, then temporarily removed, and then re-established in 1739. Its capital was Santa Fé de Bogotá. This Viceroyalty included some other provinces of northwestern South America that had previously been under the jurisdiction of the Viceroyalties of New Spain or Peru and correspond mainly to today's Venezuela, Ecuador, and Panama. Bogotá became one of the principal administrative centers of the Spanish possessions in the New World, along with Lima and Mexico City, though it remained less developed compared to those two cities in several economic and logistical ways. Great Britain declared war on Spain in 1739, and the city of Cartagena quickly became a top target for the British. A massive British expeditionary force was dispatched to capture the city, but, after achieving initial inroads, devastating outbreaks of disease crippled their numbers, and the British were forced to withdraw. The battle became one of Spain's most decisive victories in the conflict, and secured Spanish dominance in the Caribbean until the Seven Years' War. The 18th-century priest, botanist, and mathematician José Celestino Mutis was delegated by Viceroy Antonio Caballero y Góngora to conduct an inventory of the nature of New Granada. Started in 1783, this became known as the Royal Botanical Expedition to New Granada. It classified plants and wildlife, and founded the first astronomical observatory in the city of Santa Fe de Bogotá. In July 1801 the Prussian scientist Alexander von Humboldt reached Santa Fe de Bogotá where he met with Mutis.
== General characteristics == Stichodactyla helianthus is a tropical anemone commonly known as the “Sun Anemone” and part of the order Actiniaria, which comprises the sea anemones of the class Anthozoa. Described posthumously by John Ellis in 1786, these organisms, like all Anthozoa, are documented by the absence of an operculum–a calcareous shell in a circular form. Anthozoans also possess circular mitochondrial DNA and siphonoglyphs (ciliated grooves) in the pharyngeal wall. Another predominant trait resides in the presence of the coelenteron around the centralized body cavity, which is divided by distinct septa. In terms of reproductive distinction, this species lacks a medusa stage and exhibits the polyp stage exclusively.
junk RNA Any RNA-encoded sequence, especially a transcript, that appears to have no known biological function, or whose function has no positive or a net negative effect on the fitness of the genome from which it is transcribed. Despite remaining untranslated, many non-coding RNAs still serve important functions, whereas junk RNAs are truly useless: often they are the product of accidental transcription of a junk DNA sequence, or they may result from post-transcriptional processing of primary transcripts, as with spliced-out introns. Junk RNA is usually quickly degraded by ribonucleases and other cytoplasmic enzymes.
Sources: en.wikipedia.org
=== Fl–Fu === Louis B. Flexner (1902–1996). American biochemist at the University of Pennsylvania, who worked on the biochemistry of memory and brain function. Member Natl. Acad. Sci. USA. Otto Folin (1867–1934). Swedish-American chemist at Harvard, best known for developing methods for the determination of the constituents of protein-free blood filtrates. Member Natl. Acad. Sci. USA. Karl August Folkers (1906–1997). American biochemist at Merck, known for work on the antibiotics cathomycin and cycloserine. Ivar Asbjørn Følling (1888–1973). Norwegian biochemist and geneticist who first described phenylketonuria. Sidney W. Fox (1912–1998). American biochemist at the University of Miami who worked on the production of amino acids in abiotic conditions. Heinz Fraenkel-Conrat (1910–1999). German-American biochemist at UC Berkeley, known for research on viruses such as tobacco mosaic virus. Member Natl. Acad. Sci. USA. Rosalind Franklin (1920–1958). British X-ray crystallographer at King's and Birkbeck Colleges, London, who worked on the structure of DNA Perry A. Frey (b. 1935). American biochemist at the University of Wisconsin known for work on enzyme mechanisms. Member Natl. Acad. Sci. USA. Irwin Fridovich (1929–2019). American biochemist at Duke University, who discovered superoxide dismutase and studied its mechanisms and superoxide toxicity. Member Natl. Acad. Sci. USA. Joseph S. Fruton (1912–2007). Polish-American biochemist at the Rockefeller Institute.
There have been numerous proposals and usage of decimal time, most of which were based on the day as the base unit. In dynastic China, the kè was a unit that represented 1⁄100 of a day (since redefined to 1⁄96 of a day, or 15 minutes). In France, a decimal time system in place from 1793 to 1805 divided the day into 10 hours, each divided into 100 minutes, in turn divided into 100 seconds; the French Republican calendar further extended this by assembling days into ten-day weeks. Ordinal dates and Julian days, the latter of which has seen use in astronomy as it is not subject to leap year complications, allow for the expression of a decimal portion of the day. Decimal time is frequently found in fiction, often in futuristic works. The Swatch Internet Time system is based on decimal time. Many mechanical stopwatches are of the 'decimal minute' type. These split one minute into 100 units of 0.6 s each. This makes addition and subtraction of times easier than using regular seconds.
The EU adopted the listing of PFOA in Annex A of the Stockholm Convention with Commission Delegated Regulation (EU) 2020/784 of 8 April 2020 and introduced a limit value of 0,025 mg/kg for PFOA including its salts, and at 1 mg/kg for the individual PFOA-related compounds or a combination of those compounds. They also included some specific exemptions. Among them is a time-bound exemption for PFOA in fire-fighting foam.
Moore supports hiring more probation and parole officers, pursuing police misconduct allegations, and increasing resources for law enforcement agencies. During his 2022 gubernatorial campaign, he unveiled a public safety plan that includes improving offender services, improving police diversity, and supporting and funding community-based policing and violence intervention programs. He also said that he "believes in policing with maximum accountability and appropriate intensity", and would provide funding for community-based violence intervention programs to address violent crime. In an interview with MSNBC on August 30, 2022, Moore said that he would tackle crime in Baltimore by investing in violence intervention programs like Safe Streets and We Our Us. In September 2022, Moore said he would use the "bully pulpit" of the governor's office to help recruit officers and would give the state's Fraternal Order of Police a seat at the table, telling The Washington Post, "I don't think that you can be serious about actually implementing reforms if the agencies that have to be reformed are not part of the process". In August 2025, Moore criticized Trump's decision to mobilize the National Guard in Washington, D.C. as "deeply dangerous", characterizing it as a distraction from his policies and other political problems. He also said that he would not authorize the deployment of the Maryland National Guard to police cities in Maryland and later invited Trump to walk the streets of Baltimore to see the city's public safety improvements firsthand.
Sources: en.wikipedia.org
The concomitant use of elagolix with medications that inhibit OATP1B1 may increase elagolix levels, and the use of elagolix with strong OATP1B1 inhibitors like ciclosporin and gemfibrozil, which may markedly increase elagolix exposure, is contraindicated. Elagolix is a weak to moderate inducer of CYP3A, and may decrease levels of medications that are substrates of CYP3A4. In addition, elagolix is an inhibitor of P-glycoprotein, and may increase levels of medications that are substrates of P-glycoprotein, such as digoxin. Elagolix has been found to increase exposure to digoxin and ethinylestradiol, whereas it has been found to decrease exposure to rosuvastatin, midazolam, norethisterone, norelgestromin, and norgestrel. Because combined birth control pills and other forms of combined birth control contain an estrogen, and because elagolix treats endometriosis by decreasing estrogen levels in the endometrium, these form of hormonal birth control are likely and expected to decrease the effectiveness of elagolix in the treatment of this condition. The effect of progestogen-only birth control on the effectiveness of elagolix in endometriosis is unknown. However, progestogens are antiestrogenic in the uterus, and high-dose progestin therapy is known to be effective in the treatment of endometriosis similarly to GnRH antagonists. On the basis of limited clinical research, combined birth control pills have also been found to be effective in the treatment of endometriosis, but are likely not as effective as GnRH modulator monotherapy.
==== Honeydew honey ==== Honeydew honey is made from bees taking direct secretions from trees such as pine, fir, chestnut, and oak or primarily honeydew, the sweet secretions of aphids or other plant-sap-sucking insects, to produce honey rather than from nectar. This honey has a much larger proportion of indigestibles than light floral honeys, thus causing dysentery to the bees. Honeydew honey has a stronger and less sweet flavor than nectar-based honey, and European countries have been the primary market for honeydew honey. In Greece, pine honey, a type of honeydew honey, constitutes 60–65% of honey production.
== History == In 1899, Friedrich Wilhelm Zopf reported isolating a substance from Lecidea confluens, which he named confluentin, characterised by a melting point of 147–148 °C (297–298 °F). He also found that this substance turns litmus paper red, reacts with FeCl3 to produce a red-brown colour, and decomposes into carbon dioxide, a volatile substance, and a phenol-like compound with a melting point of 52 °C upon interaction with alkali. Zopf initially proposed the formula C37H50O10 for this compound before revising it to C26H36O7, noting the updated melting point as 154 °C (309 °F). In his 1962 report of his chemical investigations into the substance, German chemist Siegfried Huneck proposed naming it 'confluentinic acid' due to the presence of the carboxylic acid functional group, aligning with the naming conventions of other lichen products. Huneck described the substance as optically inactive and noted its poor solubility in petroleum ether, ethyl acetate, and acetone, but found it readily soluble in ether, benzene, and methanol. He noted the following colour reactions: weak brownish with alcoholic FeCl3 solution, blue, green, and finally violet with potassium hydroxide and chloroform upon heating, orange to orange-red with tetrazotised benzidine, and gray-violet with p-phenylenediamine; no colouration was observed with barium hydroxide. Huneck used elemental analysis and molecular weight determination by titration to determine the molecular formula of confluentinic acid as C28H36O8.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.